Alkermes plc
Revenue Breakdown
| Fiscal Year | VIVITROL | ARISTADA and ARISTADA INITIO | LYBALVI | Product sales net (unspecified product) | Manufacturing and royalty revenues | Manufacturing revenues | Royalty revenues | License revenue | Research and development revenue | Net collaborative profit |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2021 | $343.9M | $275.4M | $8.2M | $0 | $541.8M | $0 | $0 | $3.5M | $1.0M | $0 |
| FY2022 | $379.5M | $302.1M | $96.0M | $0 | $332.0M | $0 | $0 | $2.0M | $260.0K | $0 |
| FY2023 | $400.4M | $327.7M | $191.9M | $0 | $743.4M | $0 | $0 | $0 | $19.0K | $0 |
| FY2024 | $457.3M | $346.2M | $280.0M | $0 | $474.1M | $0 | $0 | $0 | $3.0K | $0 |
| FY2025 | $467.9M | $370.0M | $346.7M | $0 | $291.3M | $0 | $0 | $0 | $0 | $0 |